From: Genes polymorphism as risk factor of recurrent urolithiasis: a systematic review and meta-analysis
Ā | Shakhssalim, 2010 | Aykan, 2015 | Lai KC, 2010 | Chou YH, 2010 | Tsai FJ, 2002 | Chen WC(CTR), 2001 | Chen WC (IL-1b), 2001 | Yamate, 2000 | Eposito, 2017 | Huang, 2005 | Rendina, 2004 | Mossetti, 2003 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Title and abstract | 1 | (a) Indicate the studyās design with a commonly used term in the title or the abstract | V | V | V | V | V | V | X | V | X | X | X | V |
(b) Provide in the abstract an informative and balanced summary of what was done and what was found | V | V | V | V | V | V | V | V | V | V | V | V | ||
Introduction | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | ||
Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | V | V | V | V | V | V | V | V | V | V | V | V |
Objectives | 3 | State specific objectives, including any prespecified hypotheses | V | V | V | V | V | V | V | V | V | V | V | V |
Methods | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | ||
Study design | 4 | Present key elements of study design early in the paper | V | V | V | V | V | V | V | V | X | X | X | V |
Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | X | X | X | X | X | V | X | X | X | X | X | X |
Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls | V | V | V | V | X | V | V | V | X | V | V | V |
(b) For matched studies, give matching criteria and the nmber of controls per case | V | V | V | V | X | X | X | X | V | X | V | X | ||
Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | V | V | V | V | V | V | X | V | V | V | X | V |
Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | V | V | V | V | V | V | V | V | V | V | V | X |
Bias | 9 | Describe any efforts to address potential sources of bias | V | V | V | V | X | X | X | X | V | X | V | V |
Study size | 10 | Explain how the study size was arrived at | V | V | V | V | V | V | V | V | V | X | V | V |
Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | V | V | V | V | V | V | V | V | X | V | X | V |
Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | V | V | V | V | V | V | V | X | V | X | V | X |
(b) Describe any methods used to examine subgroups and interactions | X | V | X | X | X | X | X | X | X | X | X | V | ||
(c) Explain how missing data were addressed | X | X | X | X | X | X | X | X | X | X | X | X | ||
(d) If applicable, explain how matching of cases and controls was addressed | V | V | V | X | X | X | X | X | X | V | X | X | ||
(e) Describe any sensitivity analyses | X | X | X | X | X | X | X | X | V | X | X | X | ||
Results | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | ||
Participants | 13* | (a) Report numbers of individuals at each stage of studyāeg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | V | V | V | V | V | V | V | V | X | X | X | V |
(b) Give reasons for non-participation at each stage | X | X | X | X | X | X | X | X | X | X | X | X | ||
(c) Consider use of a flow diagram | X | X | X | X | X | X | X | X | X | X | X | X | ||
Descriptive data | 14* | (a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders | V | V | V | X | X | X | X | X | V | X | X | X |
(b) Indicate number of participants with missing data for each variable of interest | X | X | X | X | X | X | X | X | X | V | V | V | ||
Outcome data | 15* | Report numbers in each exposure category, or summary measures of exposure | V | V | V | V | V | V | V | V | V | V | V | X |
Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included | X | X | X | X | X | X | X | X | V | X | V | V |
(b) Report category boundaries when continuous variables were categorized | V | V | V | V | V | V | V | V | X | X | X | V | ||
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | X | X | X | X | X | X | X | X | X | X | X | X | ||
Other analyses | 17 | Report other analyses doneāeg analyses of subgroups and interactions, and sensitivity analyses | X | V | X | V | X | X | X | X | V | V | V | X |
Discussion | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | ||
Key results | 18 | Summarise key results with reference to study objectives | V | V | V | V | V | V | V | V | V | V | V | V |
Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | X | V | V | X | X | X | X | X | V | X | X | V |
Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | X | V | V | V | V | V | V | V | V | V | V | X |
Generalisability | 21 | Discuss the generalisability (external validity) of the study results | X | V | V | X | X | V | X | X | V | V | V | V |
Other information | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | Ā | ||
Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | V | X | V | X | X | V | X | V | X | X | X | X |